Sotac Pharmaceuticals Stock

Sotac Pharmaceuticals EV/EBIT

The EV/EBIT (Enterprise Value to EBIT) of Sotac Pharmaceuticals (SOTAC.NS) as of Jul 24, 2026 is 14.07. In the previous year, EV/EBIT (Enterprise Value to EBIT) was 26.66 — a change of -47.21% (lower).

EV/EBIT

14.07

YoY

-47.21%

Last updated:

EV/EBIT (Enterprise Value to EBIT) of Sotac Pharmaceuticals is 2026 14.07 . EV/EBIT (Enterprise Value to EBIT) of Sotac Pharmaceuticals was 2025 26.66 . It decreases by -47.21% lower compared to the previous year.

The Sotac Pharmaceuticals EV/EBIT history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

PRICE-TO-EBIT
Date
PRICE-TO-EBIT
Jan 1, 2020
0.00 base
Jan 1, 2021
0.00 base
Jan 1, 2022
0.00 base
Jan 1, 2023
19.81 base
Jan 1, 2024
23.31 base
Jan 1, 2025
13.86 base
YEARPRICE-TO-EBIT
2025 13.86
2024 23.31
2023 19.81
2022 -
2021 -
2020 -
Access this data via the Eulerpool API
Get Free API Key

Sotac Pharmaceuticals Valuation

Details

Historical Valuation Multiples

ⓘ

Price-to-Earnings Ratio (P/E)

The P/E ratio divides Sotac Pharmaceuticals's share price by its earnings per share. It tells you how many years of current earnings you are "paying for" when you buy the stock. A P/E of 20 means you pay $20 for every $1 of annual earnings. The S&P 500 historically trades at an average P/E of roughly 15–17. A P/E significantly above that may signal high growth expectations; one below may indicate undervaluation — or declining business quality.

Price-to-Sales Ratio (P/S)

The P/S ratio divides market capitalization by total revenue. Unlike the P/E ratio, it works even for companies that are not yet profitable, making it essential for evaluating high-growth firms. A P/S below 1.0 may indicate undervaluation, while ratios above 10 are typically reserved for fast-growing tech or SaaS companies with high expected future margins.

Price-to-EBIT Ratio

This ratio relates Sotac Pharmaceuticals's market price to its operating earnings, excluding the effects of debt structure and tax jurisdiction. It is particularly useful for comparing companies across different countries or with different levels of leverage, because it focuses purely on operational profitability. Lower values suggest cheaper operational earnings.

How to Use This Chart

This chart plots Sotac Pharmaceuticals's valuation multiples over time. Compare the current P/E, P/S, and P/EBIT to their own historical averages — if the current ratio is well below the multi-year average, the stock may be relatively cheap compared to its own track record. Combine this with industry comparisons: a P/E that looks high in absolute terms may be justified if Sotac Pharmaceuticals grows earnings faster than its peers.

Sotac Pharmaceuticals Stock analysis

What does Sotac Pharmaceuticals do? Sotac Pharmaceuticals is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Sotac Pharmaceuticals stock

EV/EBIT (Enterprise Value to EBIT) of Sotac Pharmaceuticals is 14.07 in 2026.

Access this data via the Eulerpool API
Get Free API Key

Valuation — Sotac Pharmaceuticals

P/EP/SEV/EBITP/BP/CFP/FCFPEGEV/RevenueEV/EBITDAEV/FCFEarnings YieldFCF YieldMarket capitalizationEnterprise ValueEV/EBITForward P/EP/TBVShareholder YieldBuyback YieldDiv.-Adj. PEGEV/OCF

All Key Metrics — Sotac Pharmaceuticals